Qureator develops Microphysiological Systems (MPS) and Curiochips microfluidic technology to create high-throughput, 3D co-culture disease models that better recapitulate tissue microenvironments. Its platforms enable patient-derived models, target validation in 3D co-cultures, high-throughput screening, biomarker identification, and more predictive clinical response assessment. The company already targets applications across oncology, vascular biology, the blood–brain barrier, and other tissue-specific pathological models. Qureator plans to use the new funding to accelerate research activities and expand into additional disease areas. The company, formerly known as Curiochips, emphasizes improving clinical translatability compared with traditional animal models. Qureator is led by CEO Kyu Baek, who has a background in electrical and biomedical engineering research.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2022